Chickenpox and asymptomatic COVID-19 after first cycle of alemtuzumab for multiple sclerosis.

Habek, Mario

Habek, Mario.

Habek M; Department of Neurology, Referral Center for Autonomic Nervous System Disorders, University Hospital Center Zagreb, Kispaticeva 12, 10000, Zagreb, Croatia. mhabek@mef.hr.

Neurol Sci ; 42(10): 4003-4005, 2021 10.

Article in English | MEDLINE | ID: covidwho-1333077

Subject(s)

COVID-19; Chickenpox; Multiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis; Alemtuzumab/adverse effects; Humans; Immunologic Factors; Multiple Sclerosis/drug therapy; Multiple Sclerosis, Relapsing-Remitting/drug therapy; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Chickenpox / Multiple Sclerosis, Relapsing-Remitting / COVID-19 / Multiple Sclerosis Limits: Humans Language: English Journal: Neurol Sci Journal subject: Neurology Year: 2021 Document Type: Article Affiliation country: S10072-021-05495-6

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google